%0 Journal Article %J J Pediatr Gastroenterol Nutr %D 2019 %T Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study. %A Naviglio, Samuele %A Lacorte, Doriana %A Lucafò, Marianna %A Cifù, Adriana %A Favretto, Diego %A Cuzzoni, Eva %A Silvestri, Tania %A Pozzi Mucelli, Martina %A Radillo, Oriano %A Decorti, Giuliana %A Fabris, Martina %A Bramuzzo, Matteo %A Taddio, Andrea %A Stocco, Gabriele %A Alvisi, Patrizia %A Ventura, Alessandro %A Martelossi, Stefano %X

OBJECTIVES: Anti-tumor necrosis factor antibodies have led to a revolution in the treatment of inflammatory bowel diseases (IBD); however, a sizable proportion of patients does not respond to therapy. There is increasing evidence suggesting that treatment failure may be classified as mechanistic (pharmacodynamic), pharmacokinetic, or immune-mediated. Data regarding the contribution of these factors in children with IBD treated with infliximab (IFX) are still incomplete. The aim was to assess the causes of treatment failure in a prospective cohort of pediatric patients treated with IFX.

METHODS: This observational study considered 49 pediatric (median age 14.4) IBD patients (34 Crohn disease, 15 ulcerative colitis) treated with IFX. Serum samples were collected at 6, 14, 22 and 54 weeks, before IFX infusions. IFX and anti-infliximab antibodies (AIA) were measured using enzyme linked immunosorbent assays. Disease activity was determined by Pediatric Crohn's Disease Activity Index or Pediatric Ulcerative Colitis Activity Index.

RESULTS: Clinical remission, defined as a clinical score <10, was obtained by 76.3% of patients at week 14 and by 73.9% at week 54. Median trough IFX concentration was higher at all time points in patients achieving sustained clinical remission. IFX levels during maintenance correlated also with C-reactive protein, albumin, and fecal calprotectin. After multivariate analysis, IFX concentration at week 14 >3.11 μg/mL emerged as the strongest predictor of sustained clinical remission. AIA concentrations were correlated inversely with IFX concentrations and directly with adverse reactions.

CONCLUSIONS: Most cases of therapeutic failure were associated with low serum drug levels. IFX trough levels at the end of induction are associated with sustained long-term response.

%B J Pediatr Gastroenterol Nutr %V 68 %P 37-44 %8 2019 Jan %G eng %N 1 %1 http://www.ncbi.nlm.nih.gov/pubmed/30211845?dopt=Abstract %R 10.1097/MPG.0000000000002112 %0 Journal Article %J Inflamm Bowel Dis %D 2017 %T Multicentric Case-Control Study on Azathioprine Dose and Pharmacokinetics in Early-onset Pediatric Inflammatory Bowel Disease. %A Stocco, Gabriele %A Martelossi, Stefano %A Arrigo, Serena %A Barabino, Arrigo %A Aloi, Marina %A Martinelli, Massimo %A Miele, Erasmo %A Knafelz, Daniela %A Romano, Claudio %A Naviglio, Samuele %A Favretto, Diego %A Cuzzoni, Eva %A Franca, Raffaella %A Decorti, Giuliana %A Ventura, Alessandro %K Adolescent %K Age of Onset %K Antimetabolites %K Azathioprine %K Case-Control Studies %K Child %K Child, Preschool %K Chromatography, High Pressure Liquid %K Dose-Response Relationship, Drug %K Erythrocytes %K Female %K Guanine Nucleotides %K Humans %K Inflammatory Bowel Diseases %K Male %K Mercaptopurine %K Methyltransferases %K Thioguanine %X

BACKGROUND: Early-onset inflammatory bowel disease (IBD) is generally aggressive, with a high probability of complications and need of surgery. Despite the introduction of highly effective biological drugs, treatment with azathioprine continues to be important even for early-onset IBD; however, in these patients azathioprine response seems to be reduced. This study evaluated azathioprine doses, metabolite concentrations, and their associations with patients' age in children with IBD treated at 6 tertiary pediatric referral centers.

METHODS: Azathioprine doses, metabolites, and clinical effects were assessed after at least 3 months of therapy in 17 early-onset (age < 6 yr, cases) and 51 nonearly-onset (aged > 12 and <18 yrs, controls) patients with IBD. Azathioprine dose was titrated on therapeutic efficacy (response and adverse effects). Azathioprine metabolites and thiopurine methyltransferase activity were determined by high-performance liquid chromatography with ultra violet-vis detection (HPLC-UV) methods.

RESULTS: Frequency of patients in remission was similar among early-onset and control groups, respectively (82% and 84%, P value = 0.72). Early-onset patients required higher doses of azathioprine (median 2.7 versus 2.0 mg·kg·d, P value = 1.1 × 10). Different doses resulted in comparable azathioprine active thioguanine nucleotide metabolite concentrations (median 263 versus 366 pmol/8 × 10 erythrocytes, P value = 0.41) and methylmercaptopurine nucleotide concentrations (median 1455 versus 1532 pmol/8 × 10 erythrocytes, P value = 0.60). Lower ratios between thioguanine nucleotide metabolites and azathioprine doses were found in early-onset patients (median 98 versus 184 pmol/8 × 10 erythrocytes·mg·kg·d, P value = 0.017). Interestingly, early-onset patients presented also higher thiopurine methyltransferase activity (median 476 versus 350 nmol methylmercaptopurine/mg hemoglobin/h, P-value = 0.046).

CONCLUSIONS: This study demonstrated that patients with early-onset IBD present increased inactivating azathioprine metabolism, likely because of elevated activity of the enzyme thiopurine methyltransferase.

%B Inflamm Bowel Dis %V 23 %P 628-634 %8 2017 04 %G eng %N 4 %1 http://www.ncbi.nlm.nih.gov/pubmed/28296824?dopt=Abstract %R 10.1097/MIB.0000000000001051 %0 Journal Article %J World J Gastroenterol %D 2015 %T Failure of interferon-γ pre-treated mesenchymal stem cell treatment in a patient with Crohn's disease. %A Taddio, Andrea %A Tommasini, Alberto %A Valencic, Erica %A Biagi, Ettore %A Decorti, Giuliana %A De Iudicibus, Sara %A Cuzzoni, Eva %A Gaipa, Giuseppe %A Badolato, Raffaela %A Prandini, Alberto %A Biondi, Andrea %A Ventura, Alessandro %X

Mesenchymal stem cells (MSC) are cells of stromal origin which exhibit unlimited self-renewal capacity and pluripotency in vitro. It has recently been observed that MSC may also exert a profound immunosuppressive and anti-inflammatory effect both in vitro and in vivo with consequent potential use in autoimmune disorders. We present the case of a patient suffering from childhood-onset, multidrug resistant and steroid-dependent Crohn's disease who underwent systemic infusions of MSC, which led to a temporary reduction in CCR4, CCR7 and CXCR4 expression by T-cells, and a temporary decrease in switched memory B-cells, In addition, following MSC infusion, lower doses of steroids were needed to inhibit proliferation of the patient's peripheral blood mononuclear cells. Despite these changes, no significant clinical benefit was observed, and the patient required rescue therapy with infliximab and subsequent autologous hematopoietic stem cell transplantation. The results of biological and in vitro observations after MSC use and the clinical effects of infusion are discussed, and a brief description is provided of previous data on MSC-based therapy in autoimmune disorders.

%B World J Gastroenterol %V 21 %P 4379-84 %8 2015 Apr 14 %G eng %N 14 %1 http://www.ncbi.nlm.nih.gov/pubmed/25892890?dopt=Abstract %R 10.3748/wjg.v21.i14.4379 %0 Journal Article %J Pharmacogenomics %D 2015 %T Glucocorticoid pharmacogenetics in pediatric idiopathic nephrotic syndrome. %A Cuzzoni, Eva %A De Iudicibus, Sara %A Franca, Raffaella %A Stocco, Gabriele %A Lucafò, Marianna %A Pelin, Marco %A Favretto, Diego %A Pasini, Andrea %A Montini, Giovanni %A Decorti, Giuliana %X

Idiopathic nephrotic syndrome represents the most common type of primary glomerular disease in children: glucocorticoids (GCs) are the first-line therapy, even if considerable interindividual differences in thepir efficacy and side effects have been reported. Immunosuppressive and anti-inflammatory effects of these drugs are mainly due to the GC-mediated transcription regulation of pro- and anti-inflammatory genes. This mechanism of action is the result of a complex multistep pathway that involves the glucocorticoid receptor and several other proteins, encoded by polymorphic genes. Aim of this review is to highlight the current knowledge on genetic variants that could affect GC response, particularly focusing on children with idiopathic nephrotic syndrome.

%B Pharmacogenomics %V 16 %P 1631-48 %8 2015 Sep %G eng %N 14 %1 http://www.ncbi.nlm.nih.gov/pubmed/26419298?dopt=Abstract %R 10.2217/pgs.15.101 %0 Journal Article %J PLoS One %D 2014 %T Fate of lymphocytes after withdrawal of tofacitinib treatment. %A Piscianz, Elisa %A Valencic, Erica %A Cuzzoni, Eva %A De Iudicibus, Sara %A De Lorenzo, Elisa %A Decorti, Giuliana %A Tommasini, Alberto %K Antigens, CD %K B-Lymphocytes %K CD4-Positive T-Lymphocytes %K CD8-Positive T-Lymphocytes %K Cell Proliferation %K Drug Administration Schedule %K Humans %K Janus Kinase 3 %K Killer Cells, Natural %K Lymphocyte Activation %K Lymphocyte Count %K Phytohemagglutinins %K Piperidines %K Primary Cell Culture %K Protein Kinase Inhibitors %K Pyrimidines %K Pyrroles %X

Tofacitinib (Tofa) is an inhibitor of Janus Kinase 3, developed for the treatment of autoimmune diseases and for the prevention of transplant rejection. Due to its selective action on proliferating cells, Tofa can offer a way to block T cell activation, without toxic effects on resting cells. However, few studies have investigated the effects of Tofa on lymphocyte activation in vitro. Our aim was to study the action of Tofa on different lymphocyte subsets after in vitro stimulation and to track the behaviour of treated cells after interruption of the treatment. Peripheral blood lymphocytes were stimulated in vitro with mitogen and treated with two concentrations of Tofa. After a first period in culture, cells were washed and further incubated for an additional time. Lymphocyte subsets, activation phenotype and proliferation were assessed at the different time frames. As expected, Tofa was able to reduce the activation and proliferation of lymphocytes in the first four days of treatment. In addition the drug led to a relative decrease of Natural Killer, B cells and CD8 T cells compared to CD4 T cells. However, treated cells were still viable after the first period in culture and begun to proliferate, strikingly, in a dose dependent manner when the drug was removed from the environment by replacing the culture medium. This novel data does not necessarily predict a similar behaviour in vivo, but can warn about the clinical use of this drug when a discontinuation of treatment with Tofa is considered for any reason.

%B PLoS One %V 9 %P e85463 %8 2014 %G eng %N 1 %1 http://www.ncbi.nlm.nih.gov/pubmed/24416411?dopt=Abstract %R 10.1371/journal.pone.0085463 %0 Journal Article %J World J Gastroenterol %D 2014 %T Pharmacogenetics of azathioprine in inflammatory bowel disease: a role for glutathione-S-transferase? %A Stocco, Gabriele %A Pelin, Marco %A Franca, Raffaella %A De Iudicibus, Sara %A Cuzzoni, Eva %A Favretto, Diego %A Martelossi, Stefano %A Ventura, Alessandro %A Decorti, Giuliana %K 6-Mercaptopurine %K Animals %K Apoptosis %K Azathioprine %K Glutathione %K Glutathione Transferase %K Humans %K Immunosuppressive Agents %K Inflammatory Bowel Diseases %K Oxidative Stress %K Pharmacogenetics %K Polymorphism, Genetic %X

Azathioprine is a purine antimetabolite drug commonly used to treat inflammatory bowel disease (IBD). In vivo it is active after reaction with reduced glutathione (GSH) and conversion to mercaptopurine. Although this reaction may occur spontaneously, the presence of isoforms M and A of the enzyme glutathione-S-transferase (GST) may increase its speed. Indeed, in pediatric patients with IBD, deletion of GST-M1, which determines reduced enzymatic activity, was recently associated with reduced sensitivity to azathioprine and reduced production of azathioprine active metabolites. In addition to increase the activation of azathioprine to mercaptopurine, GSTs may contribute to azathioprine effects even by modulating GSH consumption, oxidative stress and apoptosis. Therefore, genetic polymorphisms in genes for GSTs may be useful to predict response to azathioprine even if more in vitro and clinical validation studies are needed.

%B World J Gastroenterol %V 20 %P 3534-41 %8 2014 Apr 7 %G eng %N 13 %1 http://www.ncbi.nlm.nih.gov/pubmed/24707136?dopt=Abstract %R 10.3748/wjg.v20.i13.3534 %0 Journal Article %J Br J Clin Pharmacol %D 2012 %T Association between BclI polymorphism in the NR3C1 gene and in vitro individual variations in lymphocyte responses to methylprednisolone. %A Cuzzoni, Eva %A De Iudicibus, Sara %A Bartoli, Fiora %A Ventura, Alessandro %A Decorti, Giuliana %K Adaptor Proteins, Signal Transducing %K Adolescent %K Adult %K Apoptosis Regulatory Proteins %K Cyclin D1 %K Dose-Response Relationship, Drug %K Female %K Genotype %K Glucocorticoids %K Humans %K Lymphocytes %K Male %K Methylprednisolone %K Middle Aged %K Polymorphism, Single Nucleotide %K Receptors, Glucocorticoid %K Young Adult %X

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: In vitro lymphocyte steroid sensitivity has been suggested as a useful tool to predict in vivo response to glucocorticoid treatment in different inflammatory chronic diseases. A correlation between genetic polymorphisms and clinical response to glucocorticoids has been demonstrated in these patients.

WHAT THIS STUDY ADDS: The BclI polymorphism in the glucocorticoid receptor (NR3C1) gene is associated with higher methylprednisolone potency in vitro. The combined evaluation of the in vitro sensitivity to methylprednisolone and BclI polymorphism could represent an aid for physicians to adjust therapy a priori. AIM To evaluate the association between the in vitro sensitivity of peripheral blood mononuclear cells (PBMCs) to methylprednisolone (MP) and the presence of genetic polymorphisms involved in glucocorticoid (GC) response.

METHODS: In vitro MP inhibition of the proliferation of lymphocytes stimulated with concanavalin A was determined. Non linear regression of dose-response data was performed computing the MP concentration required to reduce proliferation to 50% (IC(50) ). The maximum inhibition achievable at the highest MP concentration (I(max) ) was also calculated. Moreover, the Taqman technique was used to analyze the BclI polymorphism in the NR3C1 gene and the Leu155His polymorphism in the NALP1 gene.

RESULTS: A significant association between the BclI mutated genotype and an increased in vitro sensitivity to GCs was observed.

CONCLUSIONS: The a priori evaluation of the BclI polymorphism, associated with a lymphocyte proliferation assay, could represent a useful diagnostic tool for the optimization of steroid treatment.

%B Br J Clin Pharmacol %V 73 %P 651-5 %8 2012 Apr %G eng %N 4 %1 http://www.ncbi.nlm.nih.gov/pubmed/22008062?dopt=Abstract %R 10.1111/j.1365-2125.2011.04130.x %0 Journal Article %J Int Immunopharmacol %D 2011 %T Differential action of 3-hydroxyanthranilic acid on viability and activation of stimulated lymphocytes. %A Piscianz, Elisa %A Cuzzoni, Eva %A De Iudicibus, Sara %A Valencic, Erica %A Decorti, Giuliana %A Tommasini, Alberto %K 3-Hydroxyanthranilic Acid %K Boronic Acids %K Cell Survival %K Cells, Cultured %K Humans %K Lymphocyte Activation %K Lymphocytes %K Manganese %K Pyrazines %X

Lymphocytes proliferation after antigen-driven activation leads to an increase in cell count, which could last some week, until apoptosis mechanisms allow the homeostatic control of the system. During the first days of this stimulation, activated lymphocytes display high resistance to apoptosis and to most immunosuppressive drugs. According to the literature, few compounds have been described to kill recently activated cells, by inhibiting metabolic processes fundamental to proliferation. The aim of our work was to evaluate comparatively these different compounds, in order to identify the best strategy to kill cells that have undergone proliferation, while sparing the repertoire of resting cells. After preliminary experiments, 3-HAA and bortezomib were selected as the most suitable compounds for our purposes. The possible synergic effect of 3-HAA with bortezomib or with manganese ions was also assessed. 3-HAA was confirmed to be the most reliable pharmacologic approach to inhibit proliferation with acceptable toxicity on resting cells. While in the case of PHA stimulation 3-HAA led to death of most lymphocytes, only a minor percentage of cells were killed after allo-stimulation, suggesting that the effect is proportional to the percentage of stimulated lymphocytes. Manganese ions further enhanced this effect, while results with bortezomib seemed to be less consistent. These results deserve further investigations to develop new procedures for targeting activated cells with pharmacological approaches.

%B Int Immunopharmacol %V 11 %P 2242-5 %8 2011 Dec %G eng %N 12 %1 http://www.ncbi.nlm.nih.gov/pubmed/21979495?dopt=Abstract %R 10.1016/j.intimp.2011.09.009